Pulmonx to Report First Quarter 2025 Financial Results on April 30, 2025
Pulmonx (Nasdaq: LUNG), a global leader in minimally invasive treatments for lung disease, has announced it will release its first quarter 2025 financial results after market close on Wednesday, April 30, 2025.
The company will host a conference call with management to discuss the results at 1:30 p.m. PT / 4:30 p.m. ET on the same day. Investors can access both the live and archived webcast of the earnings call through the investor relations section of Pulmonx's website.
Pulmonx (Nasdaq: LUNG), leader mondiale nei trattamenti minimamente invasivi per le malattie polmonari, ha annunciato che pubblicherà i risultati finanziari del primo trimestre 2025 dopo la chiusura del mercato di mercoledì 30 aprile 2025.
L'azienda terrà una conference call con il management per discutere i risultati alle 13:30 PT / 16:30 ET dello stesso giorno. Gli investitori potranno seguire la diretta e rivedere la registrazione della conference call nella sezione relazioni con gli investitori del sito web di Pulmonx.
Pulmonx (Nasdaq: LUNG), líder mundial en tratamientos mínimamente invasivos para enfermedades pulmonares, ha anunciado que publicará sus resultados financieros del primer trimestre de 2025 después del cierre del mercado el miércoles 30 de abril de 2025.
La compañía realizará una conferencia telefónica con la dirección para analizar los resultados a la 1:30 p.m. PT / 4:30 p.m. ET ese mismo día. Los inversores podrán acceder tanto a la transmisión en vivo como a la grabación de la llamada de resultados a través de la sección de relaciones con inversores en la página web de Pulmonx.
Pulmonx (나스닥: LUNG)은 폐 질환에 대한 최소 침습 치료 분야의 글로벌 선두주자로서 2025년 4월 30일 수요일 시장 마감 후 2025년 1분기 재무 실적을 발표할 예정입니다.
회사는 같은 날 오후 1시 30분 PT / 오후 4시 30분 ET에 경영진과 함께 실적에 대해 논의하는 컨퍼런스 콜을 진행합니다. 투자자들은 Pulmonx 웹사이트의 투자자 관계 섹션을 통해 실적 발표 컨퍼런스 콜의 생중계 및 녹화 영상을 시청할 수 있습니다.
Pulmonx (Nasdaq : LUNG), leader mondial des traitements peu invasifs des maladies pulmonaires, a annoncé qu'il publierait ses résultats financiers du premier trimestre 2025 après la clôture des marchés le mercredi 30 avril 2025.
L'entreprise tiendra une conférence téléphonique avec la direction pour discuter des résultats à 13h30 PT / 16h30 ET le même jour. Les investisseurs pourront accéder à la fois à la diffusion en direct et à l'enregistrement de la conférence téléphonique via la section relations investisseurs du site web de Pulmonx.
Pulmonx (Nasdaq: LUNG), ein weltweit führendes Unternehmen für minimalinvasive Behandlungen von Lungenerkrankungen, hat angekündigt, seine Finanzergebnisse für das erste Quartal 2025 nach Börsenschluss am Mittwoch, den 30. April 2025, zu veröffentlichen.
Das Unternehmen wird am selben Tag um 13:30 Uhr PT / 16:30 Uhr ET eine Telefonkonferenz mit dem Management abhalten, um die Ergebnisse zu besprechen. Investoren können sowohl den Live-Stream als auch die Aufzeichnung des Earnings Calls über den Bereich Investor Relations auf der Pulmonx-Website abrufen.
- None.
- None.
REDWOOD CITY, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2025 after the close of trading on Wednesday, April 30, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.
A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraX™ Platform, and StratX® Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
Contact
Brian Johnston
Laine Morgan
Gilmartin Group
investors@pulmonx.com
FAQ
When will Pulmonx (LUNG) release Q1 2025 earnings?
How can investors access Pulmonx's Q1 2025 earnings call?
What time is Pulmonx (LUNG) Q1 2025 earnings conference call?
Where can I find Pulmonx's (LUNG) Q1 2025 earnings webcast?
